Recursion Pharmaceuticals Statistics
Total Valuation
RXRX has a market cap or net worth of $2.11 billion. The enterprise value is $1.68 billion.
Important Dates
The next estimated earnings date is Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RXRX has 437.06 million shares outstanding. The number of shares has increased by 57.85% in one year.
| Current Share Class | 429.71M |
| Shares Outstanding | 437.06M |
| Shares Change (YoY) | +57.85% |
| Shares Change (QoQ) | +3.62% |
| Owned by Insiders (%) | 3.98% |
| Owned by Institutions (%) | 68.22% |
| Float | 418.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 27.01 |
| Forward PS | 28.77 |
| PB Ratio | 2.28 |
| P/TBV Ratio | 5.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 26.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.58, with a Debt / Equity ratio of 0.10.
| Current Ratio | 3.58 |
| Quick Ratio | 3.33 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -302.76 |
Financial Efficiency
Return on equity (ROE) is -86.34% and return on invested capital (ROIC) is -48.30%.
| Return on Equity (ROE) | -86.34% |
| Return on Assets (ROA) | -39.08% |
| Return on Invested Capital (ROIC) | -48.30% |
| Return on Capital Employed (ROCE) | -57.08% |
| Revenue Per Employee | $80,745 |
| Profits Per Employee | -$811,415 |
| Employee Count | 800 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, RXRX has paid $17,000 in taxes.
| Income Tax | 17,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.12% in the last 52 weeks. The beta is 0.90, so RXRX's price volatility has been similar to the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | -25.12% |
| 50-Day Moving Average | 5.36 |
| 200-Day Moving Average | 6.00 |
| Relative Strength Index (RSI) | 45.88 |
| Average Volume (20 Days) | 16,072,936 |
Short Selling Information
The latest short interest is 124.08 million, so 28.39% of the outstanding shares have been sold short.
| Short Interest | 124.08M |
| Short Previous Month | 122.22M |
| Short % of Shares Out | 28.39% |
| Short % of Float | 29.65% |
| Short Ratio (days to cover) | 6.82 |
Income Statement
In the last 12 months, RXRX had revenue of $64.60 million and -$649.13 million in losses. Loss per share was -$1.80.
| Revenue | 64.60M |
| Gross Profit | -433.47M |
| Operating Income | -649.72M |
| Pretax Income | n/a |
| Net Income | -649.13M |
| EBITDA | -586.39M |
| EBIT | -649.72M |
| Loss Per Share | -$1.80 |
Full Income StatementBalance Sheet
The company has $525.11 million in cash and $88.08 million in debt, giving a net cash position of $437.04 million or $1.00 per share.
| Cash & Cash Equivalents | 525.11M |
| Total Debt | 88.08M |
| Net Cash | 437.04M |
| Net Cash Per Share | $1.00 |
| Equity (Book Value) | 919.15M |
| Book Value Per Share | 2.12 |
| Working Capital | 423.13M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$383.03 million and capital expenditures -$10.84 million, giving a free cash flow of -$393.87 million.
| Operating Cash Flow | -383.03M |
| Capital Expenditures | -10.84M |
| Free Cash Flow | -393.87M |
| FCF Per Share | -$0.90 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,005.81% |
| Pretax Margin | -1,004.88% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -57.85% |
| Shareholder Yield | -57.85% |
| Earnings Yield | -30.59% |
| FCF Yield | -18.56% |
Dividend DetailsAnalyst Forecast
The average price target for RXRX is $7.25, which is 50.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.25 |
| Price Target Difference | 50.26% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RXRX has an Altman Z-Score of 0.32 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.32 |
| Piotroski F-Score | 1 |
